Adam Gridley, Allay Therapeutics CEO
June 5, 2025 07:00 AM EDT
Financing
Startups

Ex­clu­sive: Al­lay reach­es $57.5M Se­ries D mile­stone for post-sur­gi­cal pain drug

Kyle LaHucik

Biotech Correspondent

NEW YORK — Al­lay Ther­a­peu­tics has cor­ralled $57.5 mil­lion in a Se­ries D to help it com­plete a Phase 2b pain tri­al and gear up for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Is there still hope for Sum­mit's can­cer drug buried in the da­ta?

MIT sci­en­tists’ AI mod­el one-ups Al­phaFold 3, takes on ‘fun­da­men­tal is­sue’ in drug R&D

EMA con­sid­ers se­ri­ous eye con­di­tion a ‘very rare’ side ef­fect of semaglu­tide 

At a cross­roads, biotechs are pass­ing on re­verse merg­ers in 2025

Biotech ranks as Chi­na’s best shot to sur­pass US in emerg­ing tech, re­port finds

sponsored

Cy­ti­va and Eu­rek­aBio form strate­gic part­ner­ship to ad­vance lentivi­ral vec­tor man­u­fac­tur­ing for cell and gene ther­a­py ...

A service from the Financial Times